• EN

ECDC and EMCDDA guidance. Prevention and control of infectious diseases among people who inject drugs

EMCDDA/ECDC, Stockholm, October 2011

Publication type:

Joint publications


This joint guidance report explores good public health practices that can support effective policies to reduce infections. Common blood-borne viruses in this group include HIV, hepatitis B and hepatitis C. These are mainly spread through the sharing of needles, syringes and drug preparation equipment or unprotected sexual contacts. A short (8p.) version exists.

Download as ePub (2.3 MB)
English (en)   

Download as pdf :

English (en) Latvian (lv)

Table of contents

  • Acronyms and glossary
  • Executive summary
  • Introduction
  • Core values of prevention of infections among people who inject drugs
  • Recommended interventions for the prevention of infections among people who inject drugs
  • Knowing and understanding the national situation
  • Monitoring problem drug use and responses
  • Surveillance of infections
  • Monitoring and evaluation of programmes
  • Setting targets for intervention coverage
  • Annex
  • References


EU languages

  • Croatian (translated and produced  within the framework of regional projects implemented by the EMCDDA’s Reitox and International cooperation unit)
  • Czech (translated and produced by the Office of the Government of the Czech Republic)
  • Estonian (translated and produced by National Institute for Health Development, Estonia)
  • Hungarian (translated and produced by the Hungarian national focal point)
  • Latvian
  • Polish (translated and produced with the support of the Global Drug Policy program, Open Society Foundations)

Non-EU languages





Catalogue number:


About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Tel. (351) 211 21 02 00

More contact options >>

Page last updated: Thursday, 29 October 2015